Adela Cardones

Positions:

Adjunct Associate Professor in the Department of Dermatology

Dermatology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1995

University of the Philippines (Philippines)

Resident, Dermatology, Up Pgh Medical Center, Dermatology

University of the Philippines (Philippines)

Postdoctoral Fellow, Nci/Noh Dermatology Branch

National Cancer Institute

PGY1- Medicine, preliminary year, Medicine

Good Samaritan Medical Center

PGY2-4, Dermatology Residency, Dermatology

Duke University

Staff Clinician, Dermatology

National Institutes of Health

Grants:

Effect of Dupilumab (anti-IL4R¿) on the Host-Microbe Interface in Atopic Dermatitis ATOPIC DERMATITIS RESEARCH NETWORK (ADRN)

Administered By
Dermatology
Awarded By
National Jewish Health
Role
Principal Investigator
Start Date
End Date

Quantitative Assessment of Disease Severity in Chronic Cutaneous Graft vs Host Disease

Administered By
Dermatology
Awarded By
Dermatology Foundation
Role
Principal Investigator
Start Date
End Date

Ultrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker

Administered By
Dermatology
Awarded By
MicroElastic Ultrasound Systems, Inc.
Role
Principal Investigator
Start Date
End Date

A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus)

Administered By
Dermatology
Awarded By
Argenx BVBA
Role
Principal Investigator
Start Date
End Date

An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus (ADDRESS+)

Administered By
Dermatology
Awarded By
Argenx BVBA
Role
Principal Investigator
Start Date
End Date

Publications:

Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea.

Authors
Petty, AJ; Emge, DA; Blanchard, SK; Selim, MA; Scoggins, K; Liu, B; Green, CL; Cardones, AR
MLA Citation
Petty, Amy J., et al. “Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea.J Am Acad Dermatol, Apr. 2023. Pubmed, doi:10.1016/j.jaad.2023.03.052.
URI
https://scholars.duke.edu/individual/pub1572237
PMID
37054813
Source
pubmed
Published In
Journal of the American Academy of Dermatology
Published Date
DOI
10.1016/j.jaad.2023.03.052

Association between age at symptom onset and disease severity in older patients with hidradenitis suppurativa.

Authors
Jiang, SW; Petty, AJ; Jacobs, JL; Robinson, C; Bhatia, SM; Kwock, JT; Liu, B; Green, CL; Hall, RP; Cardones, AR; Jaleel, T
MLA Citation
Jiang, Simon W., et al. “Association between age at symptom onset and disease severity in older patients with hidradenitis suppurativa.Br J Dermatol, vol. 188, no. 4, Mar. 2023, pp. 555–76. Pubmed, doi:10.1093/bjd/ljac121.
URI
https://scholars.duke.edu/individual/pub1563463
PMID
36715616
Source
pubmed
Published In
Br J Dermatol
Volume
188
Published Date
Start Page
555
End Page
576
DOI
10.1093/bjd/ljac121

A Case of Multiple Hemorrhagic Friable Nodules.

Authors
MLA Citation
Diamond, Carrie, et al. “A Case of Multiple Hemorrhagic Friable Nodules.Jama Oncol, vol. 9, no. 3, Mar. 2023, pp. 432–33. Pubmed, doi:10.1001/jamaoncol.2022.6837.
URI
https://scholars.duke.edu/individual/pub1562225
PMID
36602808
Source
pubmed
Published In
Jama Oncol
Volume
9
Published Date
Start Page
432
End Page
433
DOI
10.1001/jamaoncol.2022.6837

Rashes to Recognize in the Immunocompromised Transplant Patient: Focus on the Solid Organ Transplant Recipient

MLA Citation
Whitley, M. J., et al. “Rashes to Recognize in the Immunocompromised Transplant Patient: Focus on the Solid Organ Transplant Recipient.” Emerging Transplant Infections, edited by M. I. Morris et al., Springer, 2021.
URI
https://scholars.duke.edu/individual/pub1482562
Source
manual
Published Date

A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.

Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD involves systemic steroids, which are associated with significant morbidities. We previously found that inhibition of spleen tyrosine kinase (SYK) with fostamatinib preferentially eradicated aberrantly activated B cells in both ex vivo studies of cGVHD patient B cells, as well as in vivo mouse studies. These and other preclinical studies implicated hyper-reactive B-cell receptor signaling and increased SYK expression in the pathogenesis of cGVHD and compelled this first in-human allogeneic HCT clinical trial. We investigated the safety and efficacy of the oral SYK inhibitor, fostamatinib, for both the prevention and treatment of cGVHD. The primary objective was to evaluate the safety of fostamatinib and determine its maximum tolerated dose in the post-HCT setting. Secondary objectives included assessing the efficacy of fostamatinib in preventing and treating cGVHD, as well as examining alterations in B-cell compartments with treatment. This was a single-institution phase I clinical trial that evaluated the use of fostamatinib in allogeneic HCT patients before the development of cGVHD or at the time of steroid-refractory cGVHD (SR-cGVHD). Patients received fostamatinib at one of three dose levels using a continual reassessment algorithm to determine the maximum tolerated dose. Multiparameter flow cytometry was used to evaluate changes in B cell subpopulations over the first year of treatment with fostamatinib. Nineteen patients were enrolled in this phase I trial, with 5 in the prophylaxis arm and 14 in the therapeutic arm. One patient (5%) required discontinuation of therapy for a dose-limiting toxicity. At a median follow-up of over 3 years, no patients had cancer relapse while on fostamatinib treatment, and recurrent malignancy was observed in 1 patient 2 years after the end of therapy. In the prophylaxis arm, 1 of 5 patients (20%) developed cGVHD while on fostamatinib. In the therapeutic arm, the overall response rate was 77%, with a complete response rate of 31%. The median duration of response was 19.3 months and the 12-month failure-free survival was 69% (95% confidence interval, 48-100). Patients were able to reduce their steroid dose by a median of 80%, with 73% remaining on a lower dose at 1 year compared to baseline. There was an early reduction in the proportion of IgD-CD38hi plasmablast-like cells with fostamatinib treatment, particularly in those SR-cGVHD patients who had an eventual response. B-cell reconstitution was not significantly impacted by fostamatinib therapy after allogeneic HCT. Fostamatinib featured a favorable safety profile in the post-HCT setting. Our data suggests an early efficacy signal that was associated with effects on expected cell targets in both the prophylaxis and treatment of cGVHD, providing rationale for a phase II investigation.
Authors
Lin, C; DiCioccio, RA; Haykal, T; McManigle, WC; Li, Z; Anand, SM; Poe, JC; Bracken, SJ; Jia, W; Alyea, EP; Cardones, AR; Choi, T; Gasparetto, C; Grunwald, MR; Hennig, T; Kang, Y; Long, GD; Lopez, R; Martin, M; Minor, KK; Quinones, VLP; Sung, AD; Wiggins, K; Chao, NJ; Horwitz, ME; Rizzieri, DA; Sarantopoulos, S
MLA Citation
Lin, Chenyu, et al. “A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.Transplant Cell Ther, vol. 29, no. 3, Mar. 2023, pp. 179.e1-179.e10. Pubmed, doi:10.1016/j.jtct.2022.12.015.
URI
https://scholars.duke.edu/individual/pub1560448
PMID
36577483
Source
pubmed
Published In
Transplant Cell Ther
Volume
29
Published Date
Start Page
179.e1
End Page
179.e10
DOI
10.1016/j.jtct.2022.12.015

Research Areas:

Graft vs Host Disease
Skin--Diseases--Immunological aspects